additional areas
Various companies benefit from the biomedical profile of Campus Berlin-Buch. For example, Ascenion GmbH, a company specialized in the life sciences, provides support for public research institutions in the protection and exploitation of their intellectual property, advises spin-offs and is involved in founding companies. The Akademie der Gesundheit uses the campus labs to train professionals in the health sector.
Campus Berlin-Buch GmbH is the development and operating company of the Campus Berlin-Buch and partner for the establishment of enterprises and start-ups in the Biotech Park in Berlin-Buch.
News innovation
Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contrac...
more ...Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) resolved on June 18, 2025, to increase the share capital using company funds by € 42,343,864 to € 63,515,796.
more ...Eckert & Ziegler: Outstanding Training Quality Once Again Awarded
Eckert & Ziegler SE (ISIN DE0005659700) has been recognized by the Berlin Chamber of Industry and Commerce (IHK) for the exceptional quality of its training program for the fourth time in a row.
more ...Events Campus
09.09.2025, 09:00
From Target to Market - The BBA Biotech & Pharma Summer School
The 4-day intensive course provides a comprehensive overview of the entire drug development process in biotechnology and in the pharmaceutical industry – from the idea to the market.
more ...14.09.2025, 11:00
Tag des offenen Denkmals - Einladung auf den Wissenschaftscampus Berlin-Buch
Offenes Wissenschaftsmuseum und Führung zur Geschichte des Campus Berlin-Buch
more ...18.09.2025, 17:00
Talk im Cube: IP Strategies in Biotechnology
We are excited to continue the Talks in the Cube with a further expert discussion focused on Strategies for Intellectual Property Rights in Biotechnology.
more ...
